Cross-talk between angiotensin II and glucagon receptor signaling mediates phosphorylation of mitogen-activated protein kinases ERK 1/2 in rat glomerular mesangial cells

Biochemical Pharmacology

Volumn 71, Issue 12, 2006, Pages 1711-1719

  Li, Xiao C ^a   Carretero, Oscar A ^a   Zhuo, Jia L ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Diabetes mellitus; Glucagon; Mesangial cells; Signaling cross talk

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON RECEPTOR; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHOLIPASE C; RECEPTOR BLOCKING AGENT; WORTMANNIN;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL STIMULATION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLOMERULUS; HYPOTHESIS; MESANGIUM CELL; NONHUMAN; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANGIOTENSINS; ANIMALS; CALCIUM; CYCLIC AMP-DEPENDENT PROTEIN KINASES; GLOMERULAR MESANGIUM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C; PHOSPHORYLATION; RATS; RECEPTOR CROSS-TALK; RECEPTORS, ANGIOTENSIN; RECEPTORS, GLUCAGON;

EID: 33646525394     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2006.03.018     Document Type: Article

References (48)

1. Matthaei S., Stumvoll M., Kellerer M., and Haring H.-U. Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21 (2000) 585-618
2. Gaster B., and Hirsch I.B. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 158 (1998) 134-140
3. Nett P.C., Sollinger H.W., and Alam T. Hepatic insulin gene therapy in insulin-dependent diabetes mellitus. Am J Transplant 3 (2003) 1197-1203
4. Unger R.H., and Orci L. The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 4 (1975) 14-16
5. Shah P., Vella A., Basu A., Basu R., Schwenk W.F., and Rizza R.A. Lack of suppression of glucagons contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85 (2000) 4053-4059
6. Orskov C., Jeppesen J., Madsbad S., and Holst J.J. Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87 (1991) 415-423
7. Barnett A.H., Bain S.C., Bouter P., Karlberg B., Madsbad S., Jervell J., et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351 (2004) 1952-1961
8. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
9. Ravid M., Savin H., Jutrin I., Bental T., Katz B., and Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients. Ann Intern Med 118 (1993) 577-581
10. Reaven G.M., Chen Y.D., Golay A., Swislocki A.L., and Jaspan J.B. Documentation of hyperglucagonemia through the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64 (1987) 106-110
11. Wakelam M.J., Murphy G.J., Hruby V.J., and Houslay M.D. Activation of two signal-transduction systems in hepatocytes by glucagon. Nature (Lond) 323 (1986) 68-71
12. Rodbell M., Birnbaumer L., Pohl S.L., and Krans H.M. The glucagon-sensitive adenylyl cyclase system in plasma membranes of rat liver. V. An obligatory role of guanylnucleotides in glucagon action. J Biol Chem 246 (1971) 1877-1882
13. Mayo K.E., Miller L.J., Bataille D., Dalle S., Goke B., Thorens B., et al. International union of pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev 55 (2003) 167-194
14. 2+ signaling in BHK cells expressing cloned human glucagon receptors. Am J Physiol 274 (1998) C1552-C1562
15. Amiri F., Shaw S., Wang X., Tang J., Waller J.L., Eaton D.C., et al. Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 61 (2002) 1605-1616
16. Park S.H., Woo C.H., Kim J.H., Lee J.H., Yang I.S., Park K.M., et al. High glucose down-regulates angiotensin II binding via the PKC-MAPK-cPLA2 signal cascade in renal proximal tubule cells. Kidney Int 61 (2002) 913-925
17. Amiri F., Venema V.J., Wang X., Ju H., Venema R.C., and Marrero M.B. Hyperglycemia enhances angiotensin II-inducedjanus-activated kinase/STAT signaling in vascular smooth muscle cells. J Biol Chem 274 (1999) 32382-32386
18. Wilkes B.M., Mento P.F., and Vernace M.A. Angiotensin responsiveness in hyperfiltering and nonhyperfiltering diabetic rats. J Am Soc Nephrol 4 (1993) 1346-1353
19. Singh R., Alavi N., Singh A.K., and Leehey D.J. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48 (1999) 2066-2073
20. Kraus-Friedmann N. Hormonal regulation of hepatic gluconeogenesis. Physiol Rev 64 (1984) 170-259
21. Guder W.G. Stimulation of renal gluconeogenesis by angiotensin II. Biochim Biophys Acta 584 (1979) 507-519
22. De Gasparo M., Catt K.J., Inagami T., Wright J.W., and Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52 (2000) 415-472
23. Zhuo J.L. Monocyte chemoattractant protein-1: a key mediator of angiotensin II-induced target organ damage in hypertensive heart disease. J Hypertens 22 (2004) 451-514
24. Mezzano S., Droguett A., Burgos M.E., Ardiles L.G., Flores C.A., Aros C.A., et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int Suppl 86 (2003) S64-S70
25. Li X.C., Carretero O.A., Shao Y., and Zhuo J.L. Glucagon receptor-mediated ERK 1/2 phosphorylation in rat mesangial cells: role of protein kinase A and phospholipase C. Hypertension 47 (2006) 580-585
26. Zhang S.-L., To C., Chen X., Filep J.G., Tang S.-S., Ingelfinger J.R., et al. Essential role(s) of the intrarenal renin-angiotensin system in transforming growth factor-beta1 gene expression and induction of hypertrophy of rat kidney proximal tubular cells in high glucose. J Am Soc Nephrol 13 (2002) 302-312
27. Douglas J.G., and Hopfer U. Novel aspect of angiotensin receptors and signal transduction in the kidney. Annu Rev Physiol 56 (1994) 649-669
28. Tsiani E., Lekas P., Fantus I.G., Dlugosz J., and Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 282 (2002) E161-E169
29. Ahloulay M., Dechaux M., Hassler C., Bouby N., and Bankir L. Cyclic AMP is a hepatorenal link influencing natriuresis and contributing to glucagon-induced hyperfiltration in rats. J Clin Invest 98 (1996) 2251-2258
30. Harris P.J., Skinner S.L., and Zhuo J.L. The effects of atrial natriuretic peptide and glucagon on proximal glomerulotubular balance in anesthetized rats. J Physiol (Lond) 402 (1988) 29-42
31. Zhuo J.L., Harris P.J., and Skinner S.L. ACE inhibition prevents glucagon-induced glomerular hyperfiltration in anesthetized rats. FASEB J 17 (2003) A923 [Abstract]
32. 9] glucagons amide, a glucagon antagonist. Peptides 10 (1989) 1171-1177
33. 1 receptor-activated signaling mediates Ang IV-induced renal cortical vasoconstriction in rats. Am J Physiol Renal Physiol 290 5 (2006) F1024-F1033
34. Leehey D.J., Singh A.K., Alavi N., and Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 77 (2000) S93-S98
35. 1a receptor-mediated accumulation of extracellular Ang II in proximal tubule cells: role of cytoskeleton microtubules and tyrosine phosphatase. Am J Physiol Renal Physiol; 2006 Feb 14 [Epub ahead of print].
36. 2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Hypertension 33 1 Pt 2 (1999) 347-353
37. Kang M.J., Wu X., and Ly H. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kidney Int 55 (1999) 2203-2214
38. Sevetson B.R., Kong X., and Lawrence Jr. J.C. Increasing cAMP attenuates activation of mitogen-activated protein kinase. Proc Natl Acad Sci 90 (1993) 10305-10309
39. Dalle S., Longuet C., Costes S., Broca C., Faruque O., Fontes G., et al. Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK [1/2] in MIN6 cell line and isolated islets of Langerhans. J Biol Chem 279 (2004) 20345-20355
40. 2 receptors. Kidney Int 61 (2002) 1986-1995
41. Zhuo J.L., Allen A.M., Alcorn D., MacGregor D., Aldred G.P., and Mendelsohn F.A.O. The distribution of angiotensin II receptors. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis, and management. 2nd ed (1995), Raven Press, New York 1739-1762
42. Tang E.K., and Houslay M.D. Glucagon, vasopressin and angiotensin all elicit a rapid, transient increase in hepatocyte protein kinase C activity. Biochem J 283 (1992) 341-346
43. Jiang Y., Cypess A.M., Muse E.D., Wu C.R., Unson C.G., Merrifield R.B., et al. Glucagon receptor activates extracellular signal-regulated protein kinase 1/2 via cAMP-dependent protein kinase. Proc Natl Acad Sci 98 (2001) 10102-10107
44. 2+ influx through L-type voltage-gated calcium channels mediated raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta cells. J Biol Chem 277 (2002) 48146-48151
45. Ichihara S., Senbonmatsu T., Price Jr. E., Ichiki T., Gaffney F.A., and Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. Circulation 104 (2001) 346-351
46. Yan X., Price R.L., Nakayama M., Ito K., Schuldt A.J., Manning W.J., et al. Ventricular-specific expression of angiotensin II type 2 receptors causes dilated cardiomyopathy and heart failure in transgenic mice. Am J Physiol Heart Circ Physiol 285 (2003) H2179-H2187
47. 2 receptor stimulates ERK1 and ERK2 in quiscent but inhibits ERK in NGF-stimulated PC12W cells. Mol Brain Res 78 (2000) 175-180
48. D'Amore A., Black M.J., and Thomas W.G. The angiotensin II type 2 receptor causes constitutive growth of cardiomyocytes and does not antagonize angiotensin II type 1 receptor-mediated hypertrophy. Hypertension 46 (2005) 1347-1754